Biotech Values

[mcbio]

I posted here some of my comments after a quick read of the PFE tofacitinib briefing documents.

www.siliconinvestor.com/readmsg.aspx?msgid=28130345

Anyone interested in current or future RA drugs would do themselves a great service by reading these documents.

Question on the potential malignancy risk in man. Do you think this potential concern is something specific to JAK inhibitors or is the potential concern broader? I ask because I'm curious if RIGL's fostamatinib, which is a Syk inhibitor, might not share this same risk, or at least the same degree of risk, and could have a potential advantage on this point.